How much did AB Science achieve in EBIT for the current year?
In the current year, AB Science has achieved an EBIT of 0 EUR.
AB Science EBIT 2024
AB Science EBIT
0 EUR
Ticker
AB.PA
ISIN
FR0010557264
WKN
A1CXBG
In 2024, AB Science's EBIT was 0 EUR, a 0% increase from the -13.43 M EUR EBIT recorded in the previous year.
The AB Science EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
AB Science Revenue, EBIT, Net Income FR0010557264 · A1CXBG
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AB Science, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AB Science from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AB Science’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AB Science. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AB Science’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AB Science’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AB Science’s growth potential.
AB Science Revenue, EBIT and net profit per share
| Date | AB Science Revenue | AB Science EBIT | AB Science Net Income |
|---|---|---|---|
| 2026e | 1.24 M undefined | -16.32 M undefined | -9.2 M undefined |
| 2025e | 1.14 M undefined | -16.42 M undefined | -10.82 M undefined |
| 2024e | 824,000 undefined | 0 undefined | -11.26 M undefined |
| 2023 | 970,000 undefined | -13.43 M undefined | -11.99 M undefined |
| 2022 | 958,000 undefined | -15.94 M undefined | -13.62 M undefined |
| 2021 | 1.61 M undefined | -13.81 M undefined | -14.46 M undefined |
| 2020 | 1.58 M undefined | -14.75 M undefined | -15.05 M undefined |
| 2019 | 1.57 M undefined | -17.47 M undefined | -21.75 M undefined |
| 2018 | 1.7 M undefined | -28.94 M undefined | -26.06 M undefined |
| 2017 | 1.74 M undefined | -28.4 M undefined | -27.12 M undefined |
| 2016 | 1.51 M undefined | -30.21 M undefined | -27.7 M undefined |
| 2015 | 2.28 M undefined | -25.96 M undefined | -26.72 M undefined |
| 2014 | 2.1 M undefined | -15.2 M undefined | -16.11 M undefined |
| 2013 | 1.93 M undefined | -13.77 M undefined | -14.61 M undefined |
| 2012 | 1.34 M undefined | -10.61 M undefined | -10.99 M undefined |
| 2011 | 1.1 M undefined | -9.72 M undefined | -9.65 M undefined |
| 2010 | 1.18 M undefined | -9.59 M undefined | -9.49 M undefined |
| 2009 | 320,000 undefined | -8.3 M undefined | -8.11 M undefined |
| 2008 | 0 undefined | -8 M undefined | -7.45 M undefined |
| 2007 | 0 undefined | -7.15 M undefined | -6.53 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 0 EUR | -7.15 M EUR | -6.53 M EUR |
| 2008 | 0 EUR | -8 M EUR | -7.45 M EUR |
| 2009 | 320,000 EUR | -8.3 M EUR | -8.11 M EUR |
| 2010 | 1.18 M EUR | -9.59 M EUR | -9.49 M EUR |
| 2011 | 1.1 M EUR | -9.72 M EUR | -9.65 M EUR |
| 2012 | 1.34 M EUR | -10.61 M EUR | -10.99 M EUR |
| 2013 | 1.93 M EUR | -13.77 M EUR | -14.61 M EUR |
| 2014 | 2.1 M EUR | -15.2 M EUR | -16.11 M EUR |
| 2015 | 2.28 M EUR | -25.96 M EUR | -26.72 M EUR |
| 2016 | 1.51 M EUR | -30.21 M EUR | -27.7 M EUR |
| 2017 | 1.74 M EUR | -28.4 M EUR | -27.12 M EUR |
| 2018 | 1.7 M EUR | -28.94 M EUR | -26.06 M EUR |
| 2019 | 1.57 M EUR | -17.47 M EUR | -21.75 M EUR |
| 2020 | 1.58 M EUR | -14.75 M EUR | -15.05 M EUR |
| 2021 | 1.61 M EUR | -13.81 M EUR | -14.46 M EUR |
| 2022 | 958,000 EUR | -15.94 M EUR | -13.62 M EUR |
| 2023 | 970,000 EUR | -13.43 M EUR | -11.99 M EUR |
| 2024e | 824,000 EUR | 0 EUR | -11.26 M EUR |
| 2025e | 1.14 M EUR | -16.42 M EUR | -10.82 M EUR |
| 2026e | 1.24 M EUR | -16.32 M EUR | -9.2 M EUR |
AB Science stock margins FR0010557264 · A1CXBG
The AB Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AB Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AB Science.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AB Science's sales revenue. A higher gross margin percentage indicates that the AB Science retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AB Science's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AB Science's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AB Science's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AB Science. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AB Science's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AB Science Margin History
| AB Science Gross margin | AB Science Profit margin | AB Science EBIT margin | AB Science Profit margin |
|---|---|---|---|
| 2026e | 60.52 % | -1,319.09 % | -743.65 % |
| 2025e | 60.52 % | -1,436.66 % | -946.99 % |
| 2024e | 60.52 % | 0 % | -1,366.98 % |
| 2023 | 60.52 % | -1,384.43 % | -1,235.57 % |
| 2022 | 96.76 % | -1,663.57 % | -1,421.19 % |
| 2021 | 93.09 % | -859.24 % | -900 % |
| 2020 | 95.64 % | -931.71 % | -950.41 % |
| 2019 | 88.48 % | -1,112.29 % | -1,384.28 % |
| 2018 | 85.42 % | -1,701.59 % | -1,532.1 % |
| 2017 | 93.04 % | -1,633.35 % | -1,559.63 % |
| 2016 | 69.96 % | -2,003.12 % | -1,836.6 % |
| 2015 | 85.16 % | -1,136.78 % | -1,169.7 % |
| 2014 | 81.43 % | -723.81 % | -767.14 % |
| 2013 | 82.9 % | -713.47 % | -756.99 % |
| 2012 | 82.09 % | -791.79 % | -820.15 % |
| 2011 | 72.73 % | -883.64 % | -877.27 % |
| 2010 | 67.8 % | -812.71 % | -804.24 % |
| 2009 | 53.13 % | -2,593.75 % | -2,534.38 % |
| 2008 | 60.52 % | 0 % | 0 % |
| 2007 | 60.52 % | 0 % | 0 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | 60.52 % | 0 % | 0 % |
| 2008 | 60.52 % | 0 % | 0 % |
| 2009 | 53.13 % | -2,593.75 % | -2,534.38 % |
| 2010 | 67.8 % | -812.71 % | -804.24 % |
| 2011 | 72.73 % | -883.64 % | -877.27 % |
| 2012 | 82.09 % | -791.79 % | -820.15 % |
| 2013 | 82.9 % | -713.47 % | -756.99 % |
| 2014 | 81.43 % | -723.81 % | -767.14 % |
| 2015 | 85.16 % | -1,136.78 % | -1,169.7 % |
| 2016 | 69.96 % | -2,003.12 % | -1,836.6 % |
| 2017 | 93.04 % | -1,633.35 % | -1,559.63 % |
| 2018 | 85.42 % | -1,701.59 % | -1,532.1 % |
| 2019 | 88.48 % | -1,112.29 % | -1,384.28 % |
| 2020 | 95.64 % | -931.71 % | -950.41 % |
| 2021 | 93.09 % | -859.24 % | -900 % |
| 2022 | 96.76 % | -1,663.57 % | -1,421.19 % |
| 2023 | 60.52 % | -1,384.43 % | -1,235.57 % |
| 2024e | 60.52 % | 0 % | -1,366.98 % |
| 2025e | 60.52 % | -1,436.66 % | -946.99 % |
| 2026e | 60.52 % | -1,319.09 % | -743.65 % |
AB Science Aktienanalyse
What does AB Science do?
AB Science SA is a biopharmaceutical company based in France that specializes in developing therapies for diseases with high medical need and unmet medical demand. The company was founded in 2001 by Alain Moussy and went public on the Paris stock exchange Euronext in 2010. AB Science SA's business model involves independently conducting research and development of new drugs while also building partnerships with other companies or institutions to optimize the value chain from research to commercialization. AB Science SA is divided into different divisions to specifically address the disease areas to be treated, including oncology and neurology. The company aims to develop innovative drugs based on scientific knowledge that meet the needs of patients suffering from severe and complex diseases. An important aspect of AB Science SA's product range is the quality of the products, with the company working on developing effective and safe therapies. A key component of AB Science SA's product range is the tyrosine kinase inhibitor masitinib. This is used in veterinary medicine and is intended to be used in both dogs and cats suffering from allergic, inflammatory, and oncological diseases. Masitinib is a selective inhibitor of tyrosine kinase that contributes to the regulation of signaling pathways found in cancer cells. It is believed that masitinib plays an important role in modulating the immune system and inhibiting cancer cells, although further studies are needed to confirm the potential therapeutic applications of masitinib. AB Science SA has made significant progress in oncology, particularly in the treatment of gastrointestinal stromal tumors and certain types of malignant tumors that are rare forms of cancer. AB Science SA has now submitted both products for an extended approval request (EA) in collaboration with US Regulatory, achieving the most significant success in the company's history. This could expedite the approval of these two products in the United States. In neurology, AB Science SA has also made significant progress and is currently developing products for the treatment of Alzheimer's disease, multiple sclerosis, and Parkinson's disease. In all of these areas, there is a significant unmet need for safe and effective medications, and AB Science SA is committed to addressing this need through the development of innovative therapies. Overall, AB Science SA is a biopharmaceutical company specializing in the development of therapies to combat diseases with high unmet medical needs. In addition to independent research and development, the company aims to build partnerships with other companies and institutions to optimize the value chain from research to commercialization. The main divisions of the company are oncology and neurology, and it has made significant progress in both areas. The increased submission of approval requests is a significant milestone in the company's history and could lead to further advancement within the industry. AB Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing AB Science's EBIT
AB Science's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of AB Science's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
AB Science's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in AB Science’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about AB Science stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company AB Science.
How has the EBIT of AB Science developed in recent years?
The EBIT of AB Science has increased by 0% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company AB Science?
The EBIT of AB Science is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does AB Science pay?
Over the past 12 months, AB Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AB Science is expected to pay a dividend of 0 EUR.
What is the dividend yield of AB Science?
The current dividend yield of AB Science is .
When does AB Science pay dividends?
AB Science pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AB Science?
AB Science paid dividends every year for the past 0 years.
What is the dividend of AB Science?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is AB Science located?
AB Science is assigned to the 'Health' sector.
Wann musste ich die Aktien von AB Science kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AB Science from 7/15/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 7/15/2024.
When did AB Science pay the last dividend?
The last dividend was paid out on 7/15/2024.
What was the dividend of AB Science in the year 2023?
In the year 2023, AB Science distributed 0 EUR as dividends.
In which currency does AB Science pay out the dividend?
The dividends of AB Science are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The AB Science stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von AB Science
Our stock analysis for AB Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AB Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
